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One-step fabrication of an organ-on-a-chip with
spatial heterogeneity using a 3D bioprinting
technology
Hyungseok Lee and Dong-Woo Cho*
Although various types of organs-on-chips have been introduced recently as tools for drug discovery, the
current studies are limited in terms of fabrication methods. The fabrication methods currently available not
only need a secondary cell-seeding process and result in severe protein absorption due to the material
used, but also have difficulties in providing various cell types and extracellular matrix (ECM) environments
for spatial heterogeneity in the organs-on-chips. Therefore, in this research, we introduce a novel 3D bio-
printing method for organ-on-a-chip applications. With our novel 3D bioprinting method, it was possible
to prepare an organ-on-a-chip in a simple one-step fabrication process. Furthermore, protein absorption
on the printed platform was very low, which will lead to accurate measurement of metabolism and drug
sensitivity. Moreover, heterotypic cell types and biomaterials were successfully used and positioned at the
desired position for various organ-on-a-chip applications, which will promote full mimicry of the natural
conditions of the organs. The liver organ was selected for the evaluation of the developed method, and
liver function was shown to be significantly enhanced on the liver-on-a-chip, which was prepared by 3D
bioprinting. Consequently, the results demonstrate that the suggested 3D bioprinting method is easier and
more versatile for production of organs-on-chips.
Introduction
In recent decades, the microfluidics-based cell culture plat-
form has been revealed as an effective experimental tool for a
wide range of biological applications, such as metabolomics,1
cell analysis,2,3 and organs-on-chips.4 In particular, organs-on-
chips, which mimic the biological environment of the human
body, are rising as innovative tools in the field of drug discov-
ery.5 The current drug discovery process requires multiple
screening steps, which include two-dimensional (2D) in vitro
cell culture and animal model tests.6 However, it is generally
known that the current 2D in vitro cell culture model, with
cells only, cannot fully mimic the natural environment of hu-
man organs; the use of animal models also leads to several
problems, such as ethical concerns, time consumption, and
inefficient test results because of the huge differences com-
pared with the human body.7 For these reasons, various types
of organs-on-chips have been introduced for simple and pre-
cise drug screening in the drug discovery process.8
Organs-on-chips have been mainly prepared using several
microengineering methods, such as soft lithography, replica
molding, and the microcontact printing technique.7,9 How-
ever, these methods not only require microengineering exper-
tise in the fabrication process and exhibit severe protein ab-
sorption due to the material used, but also have several
drawbacks in the aspect of biological structure preparation.9
For example, poor selectivity of various cell types for spatial
heterogeneity and the difficulty of providing multiple types of
extracellular matrix (ECM) environments for cell–ECM inter-
actions are the main drawbacks regarding the biological
structure preparation. Furthermore, living organisms have
complex and organized 2D-to-3D microscale structures com-
posed of multi-layers, cell types, ECMs, and many other ele-
ments,10 which could make the fabrication of organs-on-
chips difficult using the current methods. Thus, establishing
a novel microengineering method that can overcome the
aforementioned drawbacks is very important.
These days, 3D printing is used to produce functional de-
vices in diverse fields, such as tissue scaffolding,11–13
prototyping,14 electronics,15 sensors,16 and microfluidic17 re-
search, because of its capabilities in producing designed,
complex micro-architectures. Thus, a large number of studies
have reported the fabrication of microfluidic devices with 3D
printing technologies for chemical mixing, gradient genera-
tion, and sensing applications; however, most of them were
based on a stereolithography-based 3D printing
technology.17–19 Until now, no study has used cells and
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biomaterials directly during the 3D printing process to estab-
lish the organ-on-a-chip platforms. 3D bioprinting is an ad-
vanced 3D printing technology that uses cells and biomate-
rials as printing materials. The most promising advancement
of 3D bioprinting is that biocompatible polymers, ECM-based
hydrogels, and multiple cell types can be delivered simulta-
neously and positioned as intended to fabricate complex 3D
biological constructs.20,21 There have been interesting studies
that applied 3D bioprinting of a micro-organ on pre-prepared
microfluidic platforms for organ-on-a-chip applications;22–24
however, there have been no reports describing the use of
this technology for whole organ-on-a-chip fabrication includ-
ing a microfluidic system with multiple cell types and bioma-
terials for optimal biomimicry. Until recently, we have ac-
tively developed 3D bioprinting systems and methods using
multiple cell types and biomaterials for complex-shaped
heterogeneous tissue models.25 Based on our previous experi-
ence and current work, we suggest that the 3D bioprinting
method can be a good candidate to overcome the problems
of current organs-on-chips.
Here, we verify the 3D bioprinting method for organ-on-a-
chip platforms. Protein absorption on the organ-on-a-chip
platform was evaluated by comparing it with a PDMS plat-
form, and the developed method was confirmed with hetero-
typic cell types and biomaterials for application to various
organ-on-a-chip platforms, which were prepared simply in a
single printing process without a secondary cell-seeding pro-
cess. Furthermore, our method was successfully applied to a
liver-on-a-chip, showing that it is easier and more versatile in
producing organs-on-chips.
Materials and methods
Materials preparation
As a platform material for an organ-on-a-chip,
polyĲε-caprolactone) (PCL, MW = 43000–50000, Polysciences
Inc., Warrington, PA, USA) was used. PCL was printed with a
printing speed of 200 mm min−1 and a pneumatic pressure
of 500 kPa using a 200 μm nozzle. PCL was printed with a
minimum line width of 175 μm. For the preparation of the
hydrogels, 3% w/v gelatin (from porcine skin G6144-500G,
Sigma-Aldrich, St. Louis, MO, USA) hydrogels were prepared
by dissolving gelatin in serum-free M199 medium (Gibco
Invitrogen, Grand Island, NY), and 2% w/v collagen type 1
hydrogels were prepared by dissolving a lyophilized collagen
sponge (Dalim Corporation, Seoul, Korea) into 0.5 M of acetic
acid and neutralized by 10 N sodium hydroxide. Lastly, 10-
times concentrated Dulbecco's modified Eagle's culture me-
dium (DMEM, Gibco BRL, NY, USA) was added to the pH-
adjusted collagen hydrogel (1/10th of the volume) to supply
the medium to the cells during the printing process. The
printing conditions were adjusted depending on each hydro-
gel's property, and the collagen and gelatin hydrogels were
printed with minimum line widths of 300 μm and 230 μm,
respectively.
Design of an organ-on-a-chip platform
A 3D bioprinting code was generated for the printing system,
and the organ-on-a-chip platforms were printed, which is an
easy approach to fabrication of an organ-on-a-chip platform
with a complex design via 3D bioprinting. A fluidic channel
with internal dimensions of 1.5 mm × 1.5 mm × 15 mm was
prepared for multiple applications: for various organ-on-a-
chip platforms, protein absorption testing, and liver-on-a-chip
application. ECM-based hydrogels for the 3D micro-
environment were printed with a 400 μm thickness for
various organ-on-a-chip platforms and the liver-on-a-chip. For
the dye absorption test, a channel with the same internal size
as the one above was prepared by the 3D printing method
and polydimethylsiloxane (PDMS, Sylgard 184, Dow Corning
Corporation, USA) replica molding.
Measurement of the contact angle and protein absorption
Distilled water (5 μL) was dropped onto each of the PCL and
PDMS platforms, and each contact angle was measured by a
droplet analysis device (SmartDrop, Femtofab, Korea). To
compare the dye absorption of the PCL-printed and PDMS
replica-molded devices, a solution of Rhodamine B (1 μM in
phosphate-buffered saline) was pumped through the devices.
To perfuse through the devices, the dye was ejected at a flow
rate of 5 μL min−1 from the perfusion pump (Ismatec UK Co.
Weston-super-Mare, England). After perfusion for 12 hours,
each channel was cut through the vertical section, and the
absorption depth was visualized by using a confocal micro-
scope (Olympus FluoView FV1000, Tokyo, Japan).
Scanning electron microscopy
All printed constructs were dried under vacuum at room tem-
perature, then coated with platinum in a sputter coater (Ion
Sputter E-1045, Hitachi, Tokyo, Japan). An SEM system (SU-
6600, Hitachi, Tokyo, Japan), operating at 15 kV, was used to
examine the hydrogel position within the printed platform
and to analyze the printed microfluidic channels of the
organ-on-a-chip platform.
Cell preparation, labeling, and encapsulation into hydrogels
Human hepatocellular carcinoma (HepG2) cell lines and hu-
man umbilical vein endothelial cells (HUVEC) were pur-
chased from ATCC (USA) and Lonza (Basel, Switzerland), re-
spectively. HepG2 was cultured in Dulbecco's modified
Eagle's medium (DMEM, Gibco BRL, NY, USA) with 10% (v/v)
fetal bovine serum (FBS, Gibco BRL, NY, USA) and 1% (v/v)
penicillin/streptomycin (P/S, Sigma-Aldrich, St. Louis, MO,
USA) at 37 °C in a humidified 5% CO2 atmosphere. HUVEC
was cultured in a complete endothelium medium (EGM-2
BulletKit, Lonza) under the same conditions as the HepG2
cell culture. To label the cells, the HepG2 cells were incu-
bated at 37 °C in a 5% CO2 incubator for 15 min with DiI
(red) or DiO (green) fluorescent dyes. These HepG2-DiI-
labeled cells and HepG2-DiO-labeled cells were then used as
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two different representative cell types. These green and red-
labeled cells were encapsulated in collagen type 1 or gelatin
hydrogels and used in preparing various organ-on-a-chip plat-
forms. The concentration of cells used was from 1 to 5 × 106
cells ml−1. A confocal microscope (Olympus FluoView
FV1000, Tokyo, Japan) was used for visualization.
Printing of various organ-on-a-chip platforms
An empty cavity was first prepared, and cell types and ECM-
based hydrogels for the micro-environment were printed in
the prepared empty cavity. Secondly, with several layer-by-
layer processes, the side walls of the fluidic channel were
printed. The fluidic channel was also covered and sealed by
printing the housing material in a manner wherein it is
crossing above the pre-printed side walls of the fluidic chan-
nel to avoid fluid leakage. Lastly, the tube connection part
for dynamic stimulation was printed. In the process of print-
ing the tube connection, an optimal design was selected to
avoid leakage. In the described process, 2D, 3D, 3D/3D verti-
cal, 3D/3D horizontal, and 3D/2D models for various organ-
on-a-chip platforms were prepared using the 3D bioprinting
technology (Fig. 1).
Application to a liver-on-a-chip
To establish the 3D bioprinted liver-on-a-chip, HepG2 and
HUVEC cells were encapsulated in collagen type 1 and gelatin
hydrogels, respectively. Cell–hydrogel mixtures were applied
to each 2D and 3D part in the 3D/2D model. The concentra-
tion of HepG2 cells used was 2 × 107 cells ml−1, and the con-
centration of HUVEC cells used was 5 × 104 cells ml−1. Fur-
thermore, a 20 μL min−1 continuous flow of the DMEM/EGM-
2 medium was finally perfused to establish the liver-on-a-chip
system.
Liver function test
For functional assessment, each construct with the same
number of hepatocytes was cultured for 6 days. During this
period, the same amount of the sample medium was col-
lected every 2 days in all experimental groups to compare the
analysis results, and the medium was refreshed. The urea
and albumin values were quantified from the collected me-
dium. We used ELISA for the quantitative analysis of albumin
(DuoSet ELISA development system, Genzyme) and a urea as-
say kit (BioVision Research Products, Mountain View, CA,
USA) for the urea assay. For the hepatocyte viability test, sam-
ples were stained with Live/Dead kits (Life Technologies, Ger-
many). The live and dead hepatocytes were imaged using a
Zeiss LSM 510 Meta confocal microscope (Zeiss, Jena,
Germany).
Statistical analysis
All variables for urea synthesis and albumin secretion were
expressed as means ± standard deviation (SD). Evaluation of
the difference between the mean values of each group was
performed by Student's t-test, in which a p value of <0.05
was considered significant.
Results and discussion
3D bioprinting of an organ-on-a-chip platform
Fig. 2A shows a schematic illustration of the 3D bioprinting
technology for an organ-on-a-chip. Among multiple candi-
dates of biocompatible polymers for 3D bioprinting, PCL was
chosen as a housing material for the organ-on-a-chip plat-
forms. PCL is not only non-toxic, but also has a relatively low
melting point of 60 °C compared with other biocompatible
thermoplastics, resulting in high cell viability during the
printing process.
Fig. 2B shows the vertical section of a prepared channel
with a width of 1.5 mm. The width of the channel can be
controlled in the range from 200 μm to 2 mm. When the
channel width was wider than 2 mm, it was hard to maintain
the shape of the channel. When the PCL material is depos-
ited during the 3D bioprinting process, the organ-on-a-chip
platform was printed as a one-body structure. This is because
the melted PCL material was printed above the solidified
layer, and they attached and combined without an additional
sealing process. In addition, multiple cellular components
were printed and ECM-based hydrogels were used to provide
the micro-environment to the cells. Fig. 2C shows the hori-
zontal section view of an organ-on-a-chip fabricated with
Fig. 1 3D bioprinting process (vertical section, side view) of various
organ-on-a-chip platforms for the (A) 2D model, (B) 3D model, (C) 3D/
3D vertical model, (D) 3D/3D horizontal model, and (E) 3D/2D model.
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ECM-based hydrogels, where the hydrogels were located in
the fluidic channel exactly as intended. Lastly, printing of the
channel cover and the tube connection part was conducted to
apply continuous dynamic stimulation to the cells, which
could lead to better system functionality. Furthermore, the
contact angle of the organ-on-a-chip platform printed by PCL
was measured compared to that of the PDMS platform
(Fig. 2D and E). The result shows that the printed organ-on-a-
chip platform with PCL possessed hydrophobicity and had a
slightly lower water contact angle value than the PDMS plat-
form, which clearly indicate that confinement of the cell cul-
ture medium in an organ-on-a-chip can be done well.26
Evaluation of protein absorption
Protein absorption in a cell culture device is very important
for the accurate measurement of cell metabolism and drug
sensitivity. As mentioned before, most organs-on-chips have
been fabricated by soft lithography and a PDMS replica mold-
ing process.7,9 However, it is generally known that for a non-
specific/hydrophobic protein, less than approximately 500 Da
of its molecular mass can be absorbed into PDMS.27 This
protein absorption can cause major concern regarding the
cell culture in the organ-on-a-chip platform, since the culture
medium contains numerous proteins and growth factors. For
example, non-specific protein absorption onto PDMS can
change the protein level within the medium, which may se-
verely affect the cell culture conditions and functions.28 Nev-
ertheless, this issue has been ignored in many studies be-
cause of the lack of an alternative microengineering
technique.29 To compare the protein absorption into the
channel wall in our 3D bioprinted organ-on-a-chip platform
with that in the PDMS platform, two microfluidic channels
with the same internal dimensions of 1.5 mm × 1.5 mm × 15
mm were prepared with PCL and PDMS (Fig. 3A and B).
In order for the components of the medium and drugs to
permeate the cell membrane and reach the interior of the
cells, the molecular mass of the molecules must be smaller
than 500 Da.30 Therefore, rhodamine B dye with a molecular
mass of 479 Da was used as a representative protein molecule
with a molecular mass of 500 Da (the maximum molecular
mass value that can permeate the cell membrane). In the
PDMS channel platform, the absorption depth was about 400
μm; however, it was only about 50 μm in our printed channel
platform (Fig. 3C–F). Furthermore, we have calculated the ab-
sorption ratio of the dye by collecting samples from the inlet
and outlet of each platform. Compared with the inlet dye
Fig. 2 (A) Schematic illustration of the 3D bioprinting technology for
the organ-on-a-chip, (B) vertical section view of a microfluidic
channel, and (C) horizontal section view of the printed organ-on-a-
chip. Water contact angle at the organ-on-a-chip platform with (D)
PCL and (E) PDMS platforms (scale bar: 350 μm).
Fig. 3 Channels with the (A) PCL material and (B) PDMS material.
Images taken from the vertical section of the prepared (C) PCL
channel and (D) PDMS channel. Fluorescence images of the dye
absorption depth at the same vertical sections of (E) the PCL channel
and (F) PDMS channel (scale bar: 200 μm).
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concentration, 3.4% of the dye was absorbed in the channel
with PCL. In the channel with PDMS, 10.5% of the dye was
absorbed, which had about a threefold higher value than that
of PCL. The results indicate that the microfluidic channel
printed using PCL can be a suitable candidate for
maintaining the medium composition in an organ-on-a-chip,
and it will allow the drug discovery process to be more accu-
rate with 3D-bioprinted organs-on-chips. However, the PCL
material shows low optical transparency compared to PDMS
(Fig. 3C and D). The optical transparency of organs-on-chips
with a 3D bioprinting technology is one other problem that
has to be overcome in the near future. A printable biomate-
rial that possesses good optical transparency and less protein
absorption has to be developed.
Printing of various organ-on-a-chip platforms
Living organisms have complex and organized 2D-to-3D
microscale systems composed of multilayers and many other
elements, such as cells and ECM components.10 Therefore,
establishing an effective fabrication method to fully mimic
the natural conditions of an organism is important in organ-
on-a-chip preparation. Here, we have verified the possibilities
of various organ-on-a-chip platforms using the green- and
red-stained cells with ECM-based hydrogels.
Gelatin hydrogels have unique thermo-sensitive proper-
ties. These materials are in the gel state at low temperature;
however, they turn into liquid form at 37 °C. Using these gel-
atin hydrogels, gelatin hydrogels with cells were first printed.
After the incubation process, only gelatin material in the liq-
uid state was removed, and only the cell components
remained. Thus, the use of gelatin hydrogels as a printing
material followed by an incubation process at 37 °C made it
possible to deliver the cells only in the 2D state in the printed
microfluidic system (Fig. 4B). Collagen hydrogels are one of
the most commonly used biomaterials as a representative
ECM component in the bioengineering field, and have oppo-
site thermo-sensitive properties compared with gelatin hydro-
gels. At a low temperature, the collagen material is in liquid
form; however, at 37 °C, it turns into the gel state. Thus, it
was possible to make the 3D micro-environment for the cells
with encapsulation in the collagen hydrogels (Fig. 4C). By
comparing the 2D and 3D models, the morphological cell dif-
ferences were observed. The cells were observed with
stretched and scattered shapes in the 2D model; however, the
morphology of the cells in the 3D model was rounded in
shape due to the 3D micro-environment caused by the colla-
gen hydrogel the day after the 3D bioprinting process. In ad-
dition to the 2D or 3D model with a single cell type, the 3D/
3D vertical and 3D/3D horizontal models with heterotypic cell
types were fabricated, as shown in Fig. 4D and E, respectively.
These heterotypic models could be engineered due to the ad-
vancement of the 3D bioprinting technology, which can de-
liver ECM-based hydrogels and multiple cell types in an
intended space to fabricate complex 3D biological constructs.
Lastly, by applying the gelatin and collagen hydrogels to the
2D and 3D models, respectively, the 3D/2D model was suc-
cessfully prepared (Fig. 4F). The cells in the 2D and 3D parts
of the 3D/2D model showed similar cell morphology to the
individual 2D and 3D models. Thus, the results indicate that
appropriate delivery of cells and ECM-based hydrogels to the
desired positions in channels and effective preparation of
heterotypic dimensional models are possible with a 3D bio-
printing technology, which will lead to optimal biomimicry of
native organisms with organs-on-chips. We have shown that
printing of 2D cell patterns, 3D cell patterns, dividing 3D cell
patterns, and stacking cell patterns in the microfluidic chan-
nel are possible. Therefore, not only the various organ-on-a-
chip platforms suggested, but also much more complex plat-
forms can be designed and printed through a 3D bioprinting
technology. For example, the 3D/3D horizontal model and
3D/3D vertical model can be combined for a complex organ-
on-a-chip platform. Additionally, any complex patterns can be
designed and printed. Furthermore, all the cellular compo-
nents were successfully delivered by simple one-step fabrica-
tion using 3D bioprinting with high efficiency. Thus, there
Fig. 4 Various organ-on-a-chip platforms the day after the 3D
bioprinting process. (A) Z-stack confocal images from the horizontal
section view of (B) the 2D model, (C) 3D model, (D) 3D/3D vertical
model, (E) 3D/3D horizontal model, and (F) 3D/2D model (inset images
at the bottom left of B–F are schematics of the vertical sectional side
view).
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was no need for a low-efficiency secondary cell-seeding pro-
cess, which was required by most of the current organ-on-a-
chip platforms prepared by the stereolithography-based fabri-
cation methods.
Application to a liver-on-a-chip
The liver is one of the largest internal organs in the human
body and conducts numerous major activities, such as blood
purification, detoxification, and protein synthesis.31
According to reports, many pharmaceutical products have
been banned, withdrawn, or not approved because of drug-
induced liver injury.32 Thus, establishing an in vivo-like liver-
on-a-chip model could be a significant development in the
drug discovery process. In practice, multiple studies have in-
troduced the liver-on-a-chip;24,33–35 however, there still exist
many limitations, such as difficulties in providing various
cell types and ECM environments for spatial heterogeneity in
the liver-on-a-chip. For this reason, we have selected the liver
organ to confirm our 3D bioprinting technology for liver-on-a-
chip applications using two different cell types and ECM-
based hydrogels for spatial heterogeneity. Understanding the
natural environment of the liver tissue is essential to prepare
the liver-on-a-chip. Multiple cell types, such as hepatocytes,
endothelial cells, and stellate cells, compose the liver in a
complex order.36 In particular, the liver sinusoids in the liver
micro-architecture, which are mainly composed of patterned/
lined endothelial cells and hepatocytes, play a major role in
hepatocyte metabolism and detoxification, for example.23,37
Therefore, the endothelial cells and hepatocytes were applied
to each 2D and 3D part in the 3D/2D model (Fig. 5A and B)
for high-fidelity biomimicry of the liver sinusoid architecture.
Furthermore, a continuous flow of the medium was finally
perfused to establish the liver-on-a-chip system (Fig. 5C). For
the comparison groups, the following were used: 3D bio-
printed groups of hepatocytes only in the 3D model with static
culture (group 1) and hepatocytes–endothelial cells in the 3D/
2D model with static culture (group 2). From the evaluation of
the albumin and urea secretion with time, basic liver func-
tions in the three experimental groups were observed
(Fig. 5D). Basically, with the culture of hepatocytes only
(group 1), the liver function gradually decreased with time.
However, co-culturing the hepatocytes with endothelial cells
(group 2) significantly enhanced the liver functions. In addi-
tion, the liver-on-a-chip, prepared by 3D bioprinting (group 3),
showed higher absolute values of urea and albumin secretion
than those of the co-cultured groups (group 2), which were
fundamentally caused by constant perfusion of the medium
through the printed microfluidic pathways in the liver-on-a-
chip, mimicking the natural flow environment. With the per-
fusion of the medium, the liver-on-a-chip can create a more
suitable culture environment by continuously refreshing the
medium and removing waste products. Hepatocytes are the
main cells that affect the secreted albumin and urea in the
liver. Therefore, in addition to albumin/urea analysis, the he-
patocyte viability of each group was also evaluated. Compared
with the secreted albumin/urea values (Fig. 5D), we observed
a similar tendency of hepatocyte viability in each experimen-
tal group on day 6 (Fig. 5E). Furthermore, there were reports
that vascular formation is different from the shear stress in-
duced by microfluidics.38,39 Compared with the static culture,
it is reported that endothelial cells showed a stretched forma-
tion and direction related to the microfluidic pathway. There-
fore, the endothelial cells in the liver-on-a-chip will appear
more stretched and have specific direction compared with
those in group 2, which will promote mimicking of the
Fig. 5 Schematic illustration of the (A) side view of the liver-on-a-chip, (B) vertical section view of the liver-on-a-chip, and (C) perfusion system of
the liver-on-a-chip. (D) Liver function analysis with albumin and urea tests (*p < 0.05), and (E) hepatocyte viability on day 6 (scale bar: 100 μm).
Group 1: 3D bioprinted groups of hepatocytes only in the 3D model with static culture, group 2: 3D-bioprinted hepatocytes–endothelial cells in
the 3D/2D model with static culture, and group 3: 3D-bioprinted liver-on-a-chip.
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natural liver sinusoid structure. Consequently, the results
clearly show that our 3D bioprinted liver-on-a-chip has better
liver function than the static culture models, suggesting that
a 3D bioprinting technology can be applied to various organ-
on-a-chip platforms. However, in future development of
organs-on-chips, the most important thing that organs-on-
chips must possess is the much higher functionality that can
actually resemble human organ functions. Therefore, devel-
oping and studying conditions that will show higher func-
tionality have to be pursued in 3D-bioprinting-based organ-
on-a-chip research.
A 3D bioprinting technology also has the potential to be ex-
panded to body-on-a-chip development. Until now, connecting
complex organ-on-a-chip systems in a stable condition with
mimicry of the human circulatory system has been one of the
challenges yet to be conquered for body-on-a-chip research.40
Several attempts have been made, such as connecting each
organ-on-a-chip platform with tubing and combining all cell-
culture chambers on a single chip.41,42 However, problems of
bubbles and leaks into the body-on-a-chip platforms and lo-
cating different cell types in each cell culture chamber remain
as obstacles. However, the body-on-a-chip can be prepared
simply in a single-chip platform, and the printing of different
cell types in each cell culture chamber resembling human
physiological conditions can be performed through one-step
fabrication with a 3D bioprinting technology.
Conclusion
Establishing new micro-engineering methods for an organ-
on-a-chip is important to overcome drawbacks that current
organs-on-chips have. Here, we applied a 3D bioprinting
technology for organ-on-a-chip fabrication. Our platform
showed less protein absorption than the PDMS platform,
such that it enables accurate measurement of metabolism
and drug screening. Due to the advancement of the 3D bio-
printing technology, heterotypic cell types and biomaterials
were successfully used and positioned at the desired position,
and one-step fabrication of an organ-on-a-chip was possible
without a secondary cell-seeding process. Our suggested 3D
bioprinting method was applied for various organ-on-a-chip
platforms to show spatial heterogeneity, and the liver organ
was selected for the technical evaluation. Liver function was
shown to be significantly enhanced on the 3D bioprinted
liver-on-a-chip. Thus, it is easier and more versatile in produc-
ing organs-on-chips with the suggested 3D bioprinting
method. Our novel 3D bioprinting method will provide a new
research paradigm in the field of organs-on-chips develop-
ment and possibly lead to future applications for a body-on-a-
chip.
Acknowledgements
This work was supported by a National Research Foundation
of Korea (NRF) grant funded by the Korean government
(MSIP) (No. 2010-0018294). This work was supported by the
Industrial Technology Innovation Program (No. 10048358)
funded by the Ministry of Trade, Industry & Energy (MI,
Korea).
References
1 P. N. Nge, C. I. Rogers and A. T. Woolley, Chem. Rev.,
2013, 113, 2550–2583.
2 A. M. Taylor, M. Blurton-Jones, S. W. Rhee, D. H. Cribbs,
C. W. Cotman and N. L. Jeon, Nat. Methods, 2005, 2,
599–605.
3 S. Kim, H. Lee, M. Chung and N. L. Jeon, Lab Chip, 2013, 13,
1489–1500.
4 P. Neuži, S. Giselbrecht, K. Länge, T. J. Huang and A. Manz,
Nat. Rev. Drug Discovery, 2012, 11, 620–632.
5 D. Huh, B. D. Matthews, A. Mammoto, M. Montoya-Zavala,
H. Y. Hsin and D. E. Ingber, Science, 2010, 328, 1662–1668.
6 K. K. Van Rompay, Antiviral Res., 2010, 85, 159–175.
7 D. Huh, G. A. Hamilton and D. E. Ingber, Trends Cell Biol.,
2011, 21, 745–754.
8 Š. Selimović, M. R. Dokmeci and A. Khademhosseini, Curr.
Opin. Pharmacol., 2013, 13, 829–833.
9 S. N. Bhatia and D. E. Ingber, Nat. Biotechnol., 2014, 32,
760–772.
10 J. H. Yeon and J.-K. Park, BioChip J., 2007, 1, 17–27.
11 W.-Y. Yeong, C.-K. Chua, K.-F. Leong and M.
Chandrasekaran, Trends Biotechnol., 2004, 22, 643–652.
12 Y.-J. Seol, T.-Y. Kang and D.-W. Cho, Soft Matter, 2012, 8,
1730–1735.
13 B. R. Song, S. S. Yang, H. Jin, S. H. Lee, J. H. Lee, S. R. Park,
S.-H. Park and B.-H. Min, Tissue Eng. Regener. Med.,
2015, 12, 172–180.
14 N. N. Zein, I. A. Hanouneh, P. D. Bishop, M. Samaan, B.
Eghtesad, C. Quintini, C. Miller, L. Yerian and R. Klatte,
Liver Transpl., 2013, 19, 1304–1310.
15 K. Sun, T. S. Wei, B. Y. Ahn, J. Y. Seo, S. J. Dillon and J. A.
Lewis, Adv. Mater., 2013, 25, 4539–4543.
16 S. J. Leigh, R. J. Bradley, C. P. Purssell, D. R. Billson and
D. A. Hutchins, PLoS One, 2012, 7, e49365.
17 A. K. Au, W. Huynh, L. F. Horowitz and A. Folch, Angew.
Chem., Int. Ed., 2016, 55, 3862–3881.
18 K. B. Anderson, S. Y. Lockwood, R. S. Martin and D. M.
Spence, Anal. Chem., 2013, 85, 5622–5626.
19 A. I. Shallan, P. Smejkal, M. Corban, R. M. Guijt and M. C.
Breadmore, Anal. Chem., 2014, 86, 3124–3130.
20 S. V. Murphy and A. Atala, Nat. Biotechnol., 2014, 32,
773–785.
21 D. B. Kolesky, R. L. Truby, A. Gladman, T. A. Busbee, K. A.
Homan and J. A. Lewis, Adv. Mater., 2014, 26, 3124–3130.
22 R. Chang, J. Nam and W. Sun, Tissue Eng., Part C, 2008, 14,
157–166.
23 R. Chang, K. Emami, H. Wu and W. Sun, Biofabrication,
2010, 2, 045004.
24 N. S. Bhise, V. Manoharan, S. Massa, A. Tamayol, M.
Ghaderi, M. Miscuglio, Q. Lang, Y. S. Zhang, S. R. Shin and
G. Calzone, Biofabrication, 2016, 8, 014101.
Lab on a ChipPaper
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
5 
Ju
ne
 2
01
6.
 D
ow
nl
oa
de
d 
on
 3
0/
05
/2
01
8 
10
:4
7:
46
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
Lab Chip, 2016, 16, 2618–2625 | 2625This journal is © The Royal Society of Chemistry 2016
25 F. Pati, J.-H. Shim, J.-S. Lee and D.-W. Cho, Manuf. Lett.,
2013, 1, 49–53.
26 G. Comina, A. Suska and D. Filippini, Lab Chip, 2014, 14,
2978–2982.
27 S. Halldorsson, E. Lucumi, R. Gómez-Sjöberg and R. M.
Fleming, Biosens. Bioelectron., 2015, 63, 218–231.
28 J. M. Anderson, N. P. Ziats, A. Azeez, M. R. Brunstedt, S. Stack
and T. L. Bonfield, J. Biomater. Sci., Polym. Ed., 1996, 7, 159–169.
29 M.-H. Wu, S.-B. Huang and G.-B. Lee, Lab Chip, 2010, 10,
939–956.
30 R. Gomez-Sjoberg, A. A. Leyrat, B. T. Houseman, K. Shokat
and S. R. Quake, Anal. Chem., 2010, 82, 8954–8960.
31 T. Tao and J. Peng, J. Genet. Genomics, 2009, 36, 325–334.
32 E.-M. Materne, A. G. Tonevitsky and U. Marx, Lab Chip,
2013, 13, 3481–3495.
33 P. J. Lee, P. J. Hung and L. P. Lee, Biotechnol. Bioeng.,
2007, 97, 1340–1346.
34 B. J. Kane, M. J. Zinner, M. L. Yarmush and M. Toner, Anal.
Chem., 2006, 78, 4291–4298.
35 C.-T. Ho, R.-Z. Lin, W.-Y. Chang, H.-Y. Chang and C.-H. Liu,
Lab Chip, 2006, 6, 724–734.
36 P. M. van Midwoud, E. Verpoorte and G. M. Groothuis,
Integr. Biol., 2011, 3, 509–521.
37 Y. Kim and P. Rajagopalan, PLoS One, 2010, 5, e15456.
38 A. Van der Meer, A. Poot, M. Duits, J. Feijen and I. Vermes,
J. Biomed. Biotechnol., 2009, 2009, 823148.
39 A. Van der Meer, A. Poot, J. Feijen and I. Vermes,
Biomicrofluidics, 2010, 4, 011103.
40 J. B. Lee and J. H. Sung, Biotechnol. J., 2013, 8,
1258–1266.
41 A. Sin, K. C. Chin, M. F. Jamil, Y. Kostov, G. Rao and M. L.
Shuler, Biotechnol. Prog., 2004, 20, 338–345.
42 M. A. Guzzardi, C. Domenici and A. Ahluwalia, Tissue Eng.,
Part A, 2011, 17, 1635–1642.
Lab on a Chip Paper
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
5 
Ju
ne
 2
01
6.
 D
ow
nl
oa
de
d 
on
 3
0/
05
/2
01
8 
10
:4
7:
46
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
